Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy

M. Janice Lu, Joan Sorich, Maitreyee Hazarika, Mimi Kim, Giuseppe Del Priore, Allan J. Jacobs, Chang Chiang, Paul C. Liu, Eileen Fusco, John P. Curtin, Franco M. Muggia

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Although three large phase III trials have documented the benefit of IP chemotherapy, this therapy as consolidation has been studied in only a few pilot studies. These small studies have included patients with a variety of baseline prognostic characteristics, and only one series had a comparator group of surgically documented pathologic complete response to uniform systemic chemotherapy. No randomized trials have been done to assess the impact of IP consolidation on progression-free survival or survival in either positively or negatively reassessed patients. It is hoped that the current experience will trigger further consideration of future phase III trials to assess the value of IP consolidation after initial induction with chemotherapy (ie, chemical debulking).

Original languageEnglish (US)
Pages (from-to)969-975
Number of pages7
JournalHematology/Oncology Clinics of North America
Volume17
Issue number4
DOIs
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

Platinum
Ovarian Neoplasms
Drug Therapy
Induction Chemotherapy
Disease-Free Survival
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy. / Lu, M. Janice; Sorich, Joan; Hazarika, Maitreyee; Kim, Mimi; Del Priore, Giuseppe; Jacobs, Allan J.; Chiang, Chang; Liu, Paul C.; Fusco, Eileen; Curtin, John P.; Muggia, Franco M.

In: Hematology/Oncology Clinics of North America, Vol. 17, No. 4, 08.2003, p. 969-975.

Research output: Contribution to journalArticle

Lu, MJ, Sorich, J, Hazarika, M, Kim, M, Del Priore, G, Jacobs, AJ, Chiang, C, Liu, PC, Fusco, E, Curtin, JP & Muggia, FM 2003, 'Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy', Hematology/Oncology Clinics of North America, vol. 17, no. 4, pp. 969-975. https://doi.org/10.1016/S0889-8588(03)00059-5
Lu, M. Janice ; Sorich, Joan ; Hazarika, Maitreyee ; Kim, Mimi ; Del Priore, Giuseppe ; Jacobs, Allan J. ; Chiang, Chang ; Liu, Paul C. ; Fusco, Eileen ; Curtin, John P. ; Muggia, Franco M. / Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy. In: Hematology/Oncology Clinics of North America. 2003 ; Vol. 17, No. 4. pp. 969-975.
@article{37610403c39a4949b672783c7b4721fc,
title = "Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy",
abstract = "Although three large phase III trials have documented the benefit of IP chemotherapy, this therapy as consolidation has been studied in only a few pilot studies. These small studies have included patients with a variety of baseline prognostic characteristics, and only one series had a comparator group of surgically documented pathologic complete response to uniform systemic chemotherapy. No randomized trials have been done to assess the impact of IP consolidation on progression-free survival or survival in either positively or negatively reassessed patients. It is hoped that the current experience will trigger further consideration of future phase III trials to assess the value of IP consolidation after initial induction with chemotherapy (ie, chemical debulking).",
author = "Lu, {M. Janice} and Joan Sorich and Maitreyee Hazarika and Mimi Kim and {Del Priore}, Giuseppe and Jacobs, {Allan J.} and Chang Chiang and Liu, {Paul C.} and Eileen Fusco and Curtin, {John P.} and Muggia, {Franco M.}",
year = "2003",
month = "8",
doi = "10.1016/S0889-8588(03)00059-5",
language = "English (US)",
volume = "17",
pages = "969--975",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy

AU - Lu, M. Janice

AU - Sorich, Joan

AU - Hazarika, Maitreyee

AU - Kim, Mimi

AU - Del Priore, Giuseppe

AU - Jacobs, Allan J.

AU - Chiang, Chang

AU - Liu, Paul C.

AU - Fusco, Eileen

AU - Curtin, John P.

AU - Muggia, Franco M.

PY - 2003/8

Y1 - 2003/8

N2 - Although three large phase III trials have documented the benefit of IP chemotherapy, this therapy as consolidation has been studied in only a few pilot studies. These small studies have included patients with a variety of baseline prognostic characteristics, and only one series had a comparator group of surgically documented pathologic complete response to uniform systemic chemotherapy. No randomized trials have been done to assess the impact of IP consolidation on progression-free survival or survival in either positively or negatively reassessed patients. It is hoped that the current experience will trigger further consideration of future phase III trials to assess the value of IP consolidation after initial induction with chemotherapy (ie, chemical debulking).

AB - Although three large phase III trials have documented the benefit of IP chemotherapy, this therapy as consolidation has been studied in only a few pilot studies. These small studies have included patients with a variety of baseline prognostic characteristics, and only one series had a comparator group of surgically documented pathologic complete response to uniform systemic chemotherapy. No randomized trials have been done to assess the impact of IP consolidation on progression-free survival or survival in either positively or negatively reassessed patients. It is hoped that the current experience will trigger further consideration of future phase III trials to assess the value of IP consolidation after initial induction with chemotherapy (ie, chemical debulking).

UR - http://www.scopus.com/inward/record.url?scp=10744227981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744227981&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(03)00059-5

DO - 10.1016/S0889-8588(03)00059-5

M3 - Article

C2 - 12959186

AN - SCOPUS:10744227981

VL - 17

SP - 969

EP - 975

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 4

ER -